Indeed, in a large cohort of patients with CRC, increased expression of SEMA4A, SEMA4C and SEMA4D, but not SEMA4G, is associated with reduced recurrence-free survival (Extended Data Fig. 9k). Here, SEMA4C is linked to colorectal carcinoma.